Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

E�kazan, Ahmet Emre; Soysal, Teoman

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia [Turk J Hematol]

Turk J Hematol. 2013; 30(2): 211-213 | DOI: 10.4274/Tjh.2012.0013

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Ahmet Emre E�kazan¹, Teoman Soysal²
¹Diyarbak�r Training And Research Hospital, Department Of Hematology, Diyarbak�r, Turkey
²�stanbul University Cerrahpa�a Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, �stanbul, Turkey

Dasatinib F317L BCR-ABL Mutasyonu Olan Kronik Miyeloid L�semi Hastalar�nda Etkili Olabilir

Ahmet Emre E�kazan¹, Teoman Soysal²
¹Diyarbak�r E�itim Ve Ara�t�rma Hastanesi, Hematoloji B�l�m�, Diyarbak�r, T�rkiye
²�stanbul �niversitesi Cerrahpa�a T�p Fak�ltesi, �� Hastal�klar� Anabilim Dal�, Hematoloji B�l�m�, �stanbul, T�rkiye

Ahmet Emre E�kazan, Teoman Soysal. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia. Turk J Hematol. 2013; 30(2): 211-213

Corresponding Author: Ahmet Emre E�kazan, T�rkiye

TOOLS

Full Text PDF

Download citation

RIS

EndNote

BibTex

Medlars

Procite

Reference Manager

Share with email

Send email to author

Similar articles

PubMed

Google Scholar

In authors and institutes

In titles and abstracts

In keywords

In all


	E-ISSN: 1308-5263
Archive Most Accessed Articles Most Cited Articles Aims and Scope Instructions For Authors Editorial Board Advisory Board Manuscript Submission Why to Submit Search Contact